Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3.
The effect of interleukin 3 (IL-3) on lymphokine-activated killer cell (LAK) generation in splenic lymphocytes was examined in patients with gastric cancer or idiopathic thrombocytopenic purpura (ITP). IL-3 alone did not induce any significant LAK activity from splenic lymphocytes. However, IL-3 addition to the culture with low-dose IL-2 significantly augmented the activity of LAK cells. Spleen cells precultured with IL-3 for 2 days and then added to IL-2 became more potent LAK cells than the spleen cells cultured with the same doses of IL-3 plus IL-2. Phenotypic analysis using flow cytometry demonstrated that IL-2 alone increased in cells expressing CD2+, -11+, and -16+ cells, whereas IL-3 plus IL-2 induced the expansion of CD3+ and CD8+ cells in addition to CD2+, -11+, and -16+ cells. These results suggest that IL-3 plus IL-2 phenotypically induces not only natural killer-like LAK cells (CD2+, -11+, and -16+) but T cell-like LAK cells (CD3+ and -8+). We are now investigating the characteristics of immature T cell populations in the spleen responsive to IL-3 using T-cell receptor antibody.
Okuno
K
K
First Department of Surgery, Kinki University School of Medicine, Osaka, Japan.
Ohnishi
H
H
Shilayama
Y
Y
Hirohata
T
T
Ozaki
M
M
Yasutomi
M
M
D015703:Antigens, CD; D004357:Drug Synergism; D006801:Humans; D016219:Immunotherapy, Adoptive; D066298:In Vitro Techniques; D007261:Infusions, Intra-Arterial; D007376:Interleukin-2 / Q000008:administration & dosage*; D007377:Interleukin-3 / Q000008:administration & dosage*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D016131:Lymphocyte Subsets / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology
D015703:Antigens, CD; D007376:Interleukin-2; D007377:Interleukin-3